Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.2514
Abstract: 2514 Background: To explore the safety and synergistic anti-tumor effect of fruquintinib (a VEGFR inhibitor) in combination with sintilimab (an anti-PD-1 Ab) in patients (pts) with advanced colorectal cancer (CRC) and other solid tumors. Methods:… read more here.
Keywords: 3mg continuous; cohort; 5mg intermittent; fruquintinib plus ... See more keywords